Prosecution Insights
Last updated: October 04, 2026

Orcosa Inc.

Technology area: Biotechnology & Pharmaceuticals

12 pending office actions • 8 art units • 9 examiners • 0 of 12 (0%) have an AI response strategy ready

Analysis

Orcosa Inc. manages 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 9 distinct examiners and 8 distinct art units. This distribution shows that the company's active applications are spread across several specialized divisions of the patent office rather than a single technical niche.

LUISALBERTO GONZALEZ is the busiest examiner for Orcosa, with 3 pending office actions. While he handles 3 of the 12 total actions, the other 9 actions are split among 8 different examiners. This variety in examiners and art units suggests that Orcosa must maintain a flexible prosecution strategy to address the different standards across 8 distinct art units. With 12 pending actions and 9 examiners, the company has a high ratio of examiners to cases, which may lead to diverse prosecution outcomes across the portfolio. This decentralized profile requires the company to manage 9 separate relationships at the patent office simultaneously across 8 distinct art units.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

12
Total Pending OAs
3
Non-Final OAs
8
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

5
Hard (42%)
5
Medium (42%)
2
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (25%)
§112 only1 (8%)
Double-patenting only1 (8%)
Double-patenting + other2 (17%)
Multi-statute (no §101)5 (42%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

11
Life Sciences
92% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
8% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GONZALEZ, LUISALBERTO 3 59.4% +47.2%
DAHLIN, HEATHER RAQUEL 2 41.1% +47.5%
REYNOLDS, STEVEN ALAN 1 65.9% +23.3%
MOU, LIYUAN 1 42.9% +59.0%
BELL, SARA ELIZABETH 1 68.8% +38.2%
ROBINSON, MIKHAIL O'DONNEL 1 59.2% +42.1%
KETCHAM, KAREN A 1 20.0% +38.8%
HOERNER, PAUL ELLSWORTH 1 50.0% +62.1%
WORSHAM, JESSICA N 1 56.3% +56.3%

Hard Cases (6)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18252741 IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY BELL, SARA ELIZABETH 89d overdue
18252668 CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER DAHLIN, HEATHER RAQUEL 10d overdue
18317977 USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS MOU, LIYUAN —
18252676 RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS GONZALEZ, LUISALBERTO —
18252707 RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE KETCHAM, KAREN A —
18297364 STICK COMPOSITION CONTAINING CANNABINOIDS WORSHAM, JESSICA N —

Interview Candidates (12)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18252741 IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY BELL, SARA ELIZABETH 89d overdue
18252688 RAPIDLY DISINTERGRATING COMPOSITIONS AND METHODS (Nicotine) GONZALEZ, LUISALBERTO 60d overdue
18252694 IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF ALZHEIMER'S DISEASE ROBINSON, MIKHAIL O'DONNEL 23d overdue
18252668 CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER DAHLIN, HEATHER RAQUEL 10d overdue
19272094 PACKAGING FOR RAPIDLY INFUSING COMPOSITION REYNOLDS, STEVEN ALAN —
18317977 USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS MOU, LIYUAN —
18252681 RAPIDLY INFUSING COMPOSITIONS WITH SUPPLEMENTS AND TREATMENT METHODS GONZALEZ, LUISALBERTO —
18252676 RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS GONZALEZ, LUISALBERTO —

Top Art Units

Art UnitApps
1624 3
1629 2
1628 1
1625 1
1627 1
1614 1
1611 1
1615 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19272094 PACKAGING FOR RAPIDLY INFUSING COMPOSITION REYNOLDS, STEVEN ALAN — DP Non-Final OA — Pending Jul 17, 2025
18317977 USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS MOU, LIYUAN 1628 §103§112 Final Rejection — Pending May 16, 2023
18252741 IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY BELL, SARA ELIZABETH 1625 §103§112 Final Rejection 89d overdue Pending May 12, 2023
18252668 CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER DAHLIN, HEATHER RAQUEL 1629 §103§112Other Non-Final OA 10d overdue Pending May 11, 2023
18252694 IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF ALZHEIMER'S DISEASE ROBINSON, MIKHAIL O'DONNEL 1627 §112 Non-Final OA 23d overdue Pending May 11, 2023
18252688 RAPIDLY DISINTERGRATING COMPOSITIONS AND METHODS (Nicotine) GONZALEZ, LUISALBERTO 1624 §103DP Final Rejection 60d overdue Pending May 11, 2023
18252681 RAPIDLY INFUSING COMPOSITIONS WITH SUPPLEMENTS AND TREATMENT METHODS GONZALEZ, LUISALBERTO 1624 §103DP Final Rejection — Pending May 11, 2023
18252676 RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS GONZALEZ, LUISALBERTO 1624 §103§112Other Final Rejection — Pending May 11, 2023
18252707 RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE KETCHAM, KAREN A 1614 §103 Final Rejection — Pending May 11, 2023
18252693 METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY CONDITIONS WITH CANNABIDIOL OR ITS DERIVATIVES/ANALOGS DAHLIN, HEATHER RAQUEL 1629 §103Other Final Rejection — Pending May 11, 2023
18307228 RAPIDLY INFUSING PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS HOERNER, PAUL ELLSWORTH 1611 §103Other Final Rejection — Pending Apr 26, 2023
18297364 STICK COMPOSITION CONTAINING CANNABINOIDS WORSHAM, JESSICA N 1615 §103§112 Non-Final OA — Pending Apr 07, 2023

Managing Orcosa Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month